Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems. They ...
Wall Street still prices Abbott like a dividend stalwart, but overlooked moves suggest that framing may be costing investors ...
Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support. The Apple Watch can make glucose checks quicker, but it does not measure blood ...
On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results